The main pumping chamber of the heart ages differently in men and women, according to a new magnetic resonance imaging (MRI) study published online in the journal Radiology. Researchers said the findings may support different treatment approaches for men and women with heart disease.

RESPECT trial, long-term study results, TCT 2015, PFO closure, recurrent cryptogenic stroke

Long-term study results from the RESPECT trial found that closing a patent foramen ovale (PFO) with an Amplatzer PFO Occluder was superior to medical management in the prevention of recurrent cryptogenic stroke in patients who had previously experienced one.

October 16, 2015 — Enrollment has successfully concluded in its multi-center, international CE mark clinical trials MEND-II and RENASCENT-I for the assessment of the Amaranth Medical Fortitude sirolimus-eluting bioresorbable scaffold (BRS) in patients with symptomatic coronary artery disease. 

Claret embolic protection, TAVR, cerebral protection
Claret embolic protection, TAVR, cerebral protection

October 14, 2015 — Claret Medical, an innovator in cardiovascular cerebral protection, Data presented this week at Transcatheter Cardiovascular Therapeutics (TCT) 2015 showed the first definitive cognitive benefit from use of a cardiovascular cerebral protection system during transcatheter aortic valve replacement (TAVR) procedures. 
ABSORB III trial, TCT 2015, bioresorbable vascular scaffold, BVS

Results from a clinical trial showed that an everolimus-eluting bioresorbable vascular scaffold was non-inferior after one year compared to a current generation metallic drug-eluting stent (DES) in patients with coronary artery disease. Target lesion failure (TLF) was the primary endpoint for the study.

Edwards Lifesciences Corp. announced that details on the 13 first-in-human compassionate use cases with its Forma transcatheter tricuspid repair system were presented at the 27th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation.  The results of the first seven cases were also published online this week in the Journal of the American College of Cardiology.

Two new advances in stent technology announced in recent days further reinforce the effectiveness of the next-generation bioabsorbable stents. Both new stents are designed to help reduce the risk of long-term complications for patients receiving a stent and will give interventional cardiologists more options in the care of cardiovascular patients.

PARTNER II Trial, TCT 2015, Edwards Lifesciences, Sapien 3 valve, one-year results

One-year patient outcomes from the PARTNER II trial showed the low rate of 30-day complications with balloon-expandable transcatheter aortic valve replacement (TAVR) in high-risk and inoperable patients with aortic stenosis persisted with follow-up to one year.

October 15, 2015 — U.S. Food and Drug Administration (FDA) has cleared Edwards Lifesciences Sapien XT transcatheter aortic valve for aortic valve-in-valve (VIV) procedures. It became the second transcatheter valve to receive the VIV indication. The Medtronic CoreValve received the indication this past March.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now